Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R

The real-world results from the Australian PACIFIC-R subset confirm translation of the clinical benefit of post-CRT durvalumab consolidation in the pivotal PACIFIC trial to the real-world setting, showing favorable survival outcomes, irrespective of delays in durvalumab initiation post-radiation.

Authors

Victoria Bray (ORCID: https://orcid.org/0000-0002-6357-3899)
Ben Markman (ORCID: https://orcid.org/0000-0002-0080-2842)
Shankar Siva (ORCID: https://orcid.org/0000-0003-2840-0658)
Nick Pavlakis (ORCID: https://orcid.org/0000-0002-1738-0316)
Steven Kao
Leisl Packer

Institutions

The University of Sydney (AU)
Royal North Shore Hospital (AU)
Peter MacCallum Cancer Centre (AU)
Liverpool Hospital (AU)
Cabrini Hospital (AU)
Chris O’Brien Lifehouse (AU)
AstraZeneca (Australia) (AU)
Monash University (AU)

Publication Details

Journal: Cancer Treatment and Research Communications
Published: 2025-01-01
DOI: https://doi.org/10.1016/j.ctarc.2025.100929
Citations: 2
Primary Topic: Lung Cancer Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 3.04

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R

Victoria Bray, Ben Markman, Shankar Siva, Nick Pavlakis et al.

Jan 1, 2025

2 citations

Cancer Treatment and Research Communications

Lung Cancer Diagnosis and Treatment

3.04

article

Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R

Victoria Bray, Ben Markman, Shankar Siva, Nick Pavlakis, Steven Kao, Leisl Packer

January 1, 2025article en

2 citations

Abstract

The real-world results from the Australian PACIFIC-R subset confirm translation of the clinical benefit of post-CRT durvalumab consolidation in the pivotal PACIFIC trial to the real-world setting, showing favorable survival outcomes, irrespective of delays in durvalumab initiation post-radiation.

Cancer Treatment and Research CommunicationsVol. 43

The University of Sydney (AU), Royal North Shore Hospital (AU), Peter MacCallum Cancer Centre (AU), Liverpool Hospital (AU), Cabrini Hospital (AU), Chris O’Brien Lifehouse (AU), AstraZeneca (Australia) (AU), Monash University (AU)

Openalex Percentile: Top 10%

Lung Cancer Diagnosis and Treatment

3.04

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R — Victoria Bray, Ben Markman, et al. · Cancer Treatment and Research Communications (2025) | TGRS Research Map | TGRS